MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation.
Pang Z, Lu Y, Zhou G, Hui F, Xu L, Viau C, Spigelman AF, MacDonald PE, Wishart DS, Li S, Xia J. · 2024
Read MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. by Pang Z, Lu Y, Zhou G, Hui F, Xu L, Viau C, Spigelman AF, MacDonald PE, Wishart DS, Li S, Xia J. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc11223798.txt.
Introduction
Pang and a large team introduce version 6.0 of a metabolomics platform in this 2024 paper. Metabolomics reads the small molecules in a sample to reveal cell activity. The platform, MetaboAnalyst, processes and interprets such data from mass spectrometry, a method that weighs molecules to identify them. Version 6.0 pursues two goals: fuller use of tandem mass data and support for exposomics, the study of environmental exposures.
New modules headline the release. One processes spectra with support for second-stage mass data and a named algorithm called asari. Another annotates peaks against fragment-level reference databases. A causal analysis module estimates cause links using a genetic method called Mendelian randomization. A dose-response module computes benchmark doses. Pathway analysis now spans about 130 species, and visuals and databases were updated.
Catalog record
| CREATOR | Pang Z, Lu Y, Zhou G, Hui F, Xu L, Viau C, Spigelman AF, MacDonald PE, Wishart DS, Li S, Xia J. |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation By Zhiqiang Pang, Yao Lu, Guangyan Zhou, Fiona Hui, Lei Xu, Charles Viau, Aliya F Spigelman, Patrick E MacDonald, David S Wishart, Shuzhao Li, Jianguo Xia Published in: Nucleic Acids Research DOI: 10.1093/nar/gkae253 ABSTRACT Abstract We introduce MetaboAnalyst version 6.0 as a unified platform for processing, analyzing, and interpreting data from targeted as well as untargeted metabolomics studies using liquid chromatography - mass spectrometry (LC–MS). The two main objectives in developing version 6.0 are to support tandem MS (MS2) data processing and annotation, as well as to support the analysis of data from exposomics studies and related experiments. Key features of MetaboAnalyst 6.0 include: (i) a significantly enhanced Spectra Processing module with support for MS2 data and the asari algorithm; (ii) a MS2 Peak Annotation module based on comprehensive MS2 reference databases with fragment-level annotation; (iii) a new Statistical Analysis module dedicated for handling complex study design with multiple factors or phenotypic descriptors; (iv) a Causal Analysis module for estimating metabolite - phenotype causal relations based on two-sample Mendelian randomization, and (v) a Dose-Response Analysis module for benchmark dose calculations. In addition, we have also improved MetaboAnalyst's visualization functions, updated its compound database and metabolite sets, and significantly expanded its pathway analysis support to around 130 species. MetaboAnalyst 6.0 is freely available at https://www.metaboanalyst.ca. INTRODUCTION Metabolomics involves the comprehensive study of all small molecules in a biological system. It has diverse applications ranging from basic biochemical research to clinical investigation of diseases, food safety assessment, environmental monitoring, etc. (1–5). User-friendly and easily accessible bioinformatics tools are essential to deal with the complex data produced from metabolomics studies. MetaboAnalyst is a user-friendly, web-based platform developed to provide comprehensive support for metabolomics data analysis (6–10). The early versions (1.0–3.0) focused primarily on supporting statistical and functional analysis of targeted metabolomics data. Increasing support for untargeted metabolomics data from liquid chromatography–mass spectrometry (LC–MS) experiments have been gradually introduced in more recent versions of MetaboAnalyst. For instance, version 4.0 implemented a new module to support functional analysis directly from LC–MS peaks, while version 5.0 added an auto-optimized LC–MS spectral processing module that works seamlessly with the functional analysis module. A detailed protocol on how to use different modules for comprehensive analysis of untargeted metabolomics data was published in 2022 (11). According to Google Analytics, the MetaboAnalyst web server has processed over 2 million jobs, including 33 000 spectral processing jobs over the past 12 months. Many of these jobs are associated with untargeted metabolomics and exposomics studies. Untargeted metabolomics data generated from high-resolution LC–MS instruments are typically characterized by thousands of peaks with unknown chemical identities. To assist with compound identification, tandem MS (called MS/MS or MS2) spectra are often collected from pooled QC samples during the experiments (12). The two commonly used MS2 methods are data-dependent acquisition (DDA) and data-independent acquisition (DIA), with sequential window acquisition of all theoretical mass spectra (SWATH) being a promising special case of the latter. DDA data usually have clear associations between the precursor ions and the corresponding MS2 spectra, while DIA data generally require deconvolution of the MS2 data to reconstruct associations with their precursor ions (13). Incorporating MS2 processing and annotation into untargeted metabolomics workflows can greatly improve compound annotations and functional interpretation. Exposomics is an emerging field centered on profiling the complete set of exposures individuals encounter across their lifespan, which often involves MS analysis of chemical mixtures traditionally rooted in toxicology and public health (4). Untargeted LC–MS based metabolomics is increasingly applied to exposomics and toxicology studies. Exposomics data from human cohorts is often associated with complex phenotypic data due to their observational nature. This requires more sophisticated data analysis and visualization methods that can take into consideration of multiple factors or covariates. Exposomics studies typically produce long lists of potential biomarkers that are significantly associated with phenotypes of interest. Identification of causal links from this large number of metabolite-phenotype relations is a natural next step. It has become possible recently with the availability of many metabolomic genome-wide association studies (mGWAS) that link metabolites and genotypes (14–16). By integrating mGWAS data with comparable GWAS data that associate genotypes with various phenotypes (17), we can now estimate causal relationships between a metabolite and a phenotype of interest through Mendelian randomization (MR) (18). Dose-response experiments are often performed to further quantify cause-and-effect relationships. The experiments are often conducted at multiple dose levels using in vitro assays or animal models to calculate dose-response curves for risk assessment of chemical exposures (19–21). To address these emerging needs from both the metabolomics and exposomics communities, we have developed MetaboAnalyst version 6.0. This version includes many key features: - A significantly enhanced spectra processing workflow with the addition of asari algorithm for LC–MS spectra processing (22), as well as support for MS2 (DDA or SWATH-DIA) data processing. - A new module for MS2 spectral database searching for compound identification and results visualization. - A new module for causal analysis between metabolites and phenotypes of interest based on two-sample MR (2SMR). - A new module for dose-response analysis including dose-response curve fitting and benchmark dose (BMD) calculation. - A new module for statistical analysis with complex metadata; - A number of other important updates including: improved functional analysis of untargeted metabolomics data by integrating MS2-based compound identification; updated compound database, pathways and metabolite sets; as well as improved data visualization support across multiple modules. MetaboAnalyst 6.0 is feely accessible at https://www.metaboanalyst.ca, with comprehensive documentations and updated tutorials. To better engage with our users, a dedicated user forum (https://omicsforum.ca) has been operational since May 2022. To dates, this forum contains >4000 posts on ∼700 topics related to different aspects of using MetaboAnalyst. OVERALL DESIGN AND WORKFLOW OF METABOANALYST 6.0 MetaboAnalyst 6.0 accepts a total of five different data types across various modules encompassing spectra processing, statistical analysis, functional analysis, meta-analysis, and integration with other omics data. Once the data are uploaded, all analysis steps are conducted within a consistent framework including data integrity checks, parameter customization, and results visualization (Figure 1). Some of the key features in MetaboAnalyst 6.0 are described below. [Figure: MetaboAnalyst 6.0 workflow for targeted and untargeted metabolomics data. Multiple data input types are accepted. Untargeted metabolomics inputs require extra steps for spectra processing and peak annotation. The result table can be used for statistical and functional analysis within a consistent workflow in the same manner as for targeted metabolomics data.] SUPPORTING ASARI AND MS2 SPECTRA IN LC–MS SPECTRA PROCESSING WORKFLOW LC–MS spectra processing remains an active research topic in the field of untargeted metabolomics. Many powerful tools have been developed over time, including XCMS (23), MZmine (24), MS-DIAL (13) and asari (22). In addition to using different peak detection algorithms, most tools require manual parameter tuning to ensure good results. Such practice often leads to results that vary significantly (25). To mitigate this issue, MetaboAnalyst 5.0 introduced an auto-optimized LC–MS processing pipeline to minimize the parameter-related effects (10,26). The asari software has introduced a set of quality metrics, concepts of mass tracks and composite mass tracks and new algorithmic design to minimize errors in feature correspondence. It requires minimal parameter tuning while achieving much faster